Skip Ribbon Commands
Skip to main content

Title

Intentions to use pre-exposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.

Authors

Fuchs JD, Sobieszczyk ME, Madenwald T, Grove D, Karuna ST, Andrasik M, Sherwat A, Broder G, Mayer K, Koblin B, Hammer S; HVTN 505 Protocol Team.

Network Affiliation

Other

Organization

 

Journal Name

JAIDS

Publication Date

4/22/2013

PubMed Search

http://www.ncbi.nlm.nih.gov/pubmed/?term=23614998

Link to full-text

 

PMID

23614998

Abstract

In November 2010, the iPrEx study reported that pre-exposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate/emtricitabine reduced HIV infections by 44% among men who have sex with men and subsequent trials corroborated efficacy among heterosexual men and women. During regularly scheduled follow-up visits from January-March 2011, participants in an ongoing phase 2b vaccine efficacy trial completed an anonymous web survey about PrEP. Among 376 respondents, 17% reported they were very likely to use PrEP in the next year. Non-white participants were more likely to use PrEP. Among those with some level of interest, intent to use PrEP was greatest if the drug were available through the clinical trial or health insurance. Most (91%) believed taking PrEP would not change their willingness to stay in the vaccine trial and few thought it would affect recruitment. As key stakeholders, currently enrolled trial participants can offer vital input about emerging prevention technologies that may affect the design of future HIV vaccine and non-vaccine prevention trials.

Keywords

 

Topic

Adherence; Behavior; MSM; Women

Attachments

Created at 4/26/2013 11:42 AM by Davis, Gregory P
Last modified at 4/26/2013 11:42 AM by Davis, Gregory P